#AI-generated novel antibodies for over 50 top targets in less than 3 months...it's time to change the SOPs.
"The Coming Revolution of Generative Biology Geoffrey von Maltzahn joined Flagship Pioneering in 2009 and serves as general partner. He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies that integrate biology and data science to transform human health and sustainability.
Geoffrey co-founded companies that have, in aggregate, achieved over $10 billion in public and private market capitalization. Through his role in Flagship Labs, the company’s innovation foundry, Geoffrey has created companies that include Quotient Therapeutics, Tessera Therapeutics, Generate:Biomedicines, Indigo Agriculture, Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB). These are pioneering, respectively, somatic genomics, Gene Writing?, generative biology, carbon farming and plant microbiome products, engineered cells and cell-specific gene therapies, and the first human microbiome therapeutics."
Marketing Executive @ RPK Reports | Market Research
6 个月Pioneering biotechnology paves way for revolutionary breakthroughs. Exciting times ahead